Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

SIMPLE SUMMARY: In a double-blind, placebo-controlled, randomized phase 2 trial, Regorafenib provided a clinical benefit to patients with advanced and anthracycline-pretreated soft tissue sarcoma. However, extensive mutational analysis of tumor genes could not identify predictive markers of regorafe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Brodowicz, Thomas, Liegl-Atzwanger, Bernadette, Penel, Nicolas, Mir, Olivier, Blay, Jean-Yves, Kashofer, Karl, Le Cesne, Axel, Decoupigny, Emilie, Wallet, Jennifer, Hamacher, Rainer, Le Deley, Marie-Cecile
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7763753/
https://ncbi.nlm.nih.gov/pubmed/33322802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123746
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky